Drugs / INGITAMIG
INGITAMIG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04975399 | Oct 2021 → Jun 2024 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INGITAMIG | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068469 ↗ |
| Known as | BMS-986392 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068469 ↗ |
| Known as | CC-92328 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04975399 ↗ |
| Known as | DF-3001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068469 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068469 ↗ |
| Route | Intravenous | “CC-92328 administered intravenously in 28-day cycles” NCT04975399 ↗ |